

Erhan Keleş

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7756309/publications.pdf>

Version: 2024-02-01

8
papers

96
citations

1937457

4
h-index

2272820

4
g-index

8
all docs

8
docs citations

8
times ranked

97
citing authors

#	ARTICLE	IF	CITATIONS
1	(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6241-6261.	2.9	45
2	Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl- ϵ -Pyrimidine Moiety. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1473-1479.	1.3	28
3	4-(Difluoromethyl)-5-(4-((3 <i>R</i> ,5 <i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13595-13617.	2.9	17
4	Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability. <i>RSC Medicinal Chemistry</i> , 2021, 12, 579-583.	1.7	6
5	Abstract 291: Development of optimized chemical probes targeting PI3K α to deconvolute the role of class I PI3Ks isoforms in insulin signaling. , 2021, , .		0
6	Abstract 293: Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitors suitable for the treatment of CNS disorders. , 2021, , .		0
7	Abstract 1377: Volume scanning, a rational approach to covalent PI3K β inhibitors. , 2021, , .		0
8	Abstract 1378: A novel, highly potent PI3K β covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells. , 2021, , .		0